Drug Testing in Clinical Practice: When, What, Who and How
Date & Time
Wednesday, April 4, 2018, 11:15 AM - 12:30 PM
Frank James, MD, JD, FASAM, FACLM, Vice Chair, Payer Relations Committee, American Society of Addiction Medicine
Margaret Jarvis, MD, DFASAM, Director of the Division of Addiction Medicine , Neurosciences Institute at Geisinger Health System
Moderator: Robert DuPont, MD, President, Institute for Behavior and Health, Inc., and Member, National Rx Drug Abuse & Heroin Summit Advisory Board
CE Certified By: AMA,AAFP,ACPE,ADA,ANCC,APA
There has been inconsistent clinical practice and unethical and/or fraudulent activities related to drug testing, such as healthcare settings testing with unnecessary frequency and payers creating restrictive policies that have no evidentiary basis in research or clinical expertise. American Society of Addiction Medicine (ASAM) recognized that balance must be made between clinical outcomes and utility costs to improve the quality of care that patients receive and developed national guidance.
In this session, presenters will discuss the ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document in relation to improving clinical outcomes and standardizing payment models for drug testing. While all testing has pros and cons, its clinical and economic value is supreme. Participants should leave with an awareness and understanding of how to utilize the ASAM Drug Testing consensus document to determine when, where and how often it is appropriate to perform drug testing to treat their patient populations.
UPON COMPLETION OF THIS COURSE, PARTICIPANTS WILL BE ABLE TO:
- Recognize the importance of the guidance needed around drug testing today.
- Explain the duality between clinical outcomes/quality of care and utility costs.
- Summarize the ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document's recommendations and how they should be used in practice.